TFA Therapeutics, Inc.
corporate_fare Company Profile
TFA Therapeutics, Inc. (OTC:RAJAF) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 3 items for RAJAF at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-09-02, rated 7/10. Across its 3 most recent items scored 7 or higher, the top rating is 9/10, with 2 rated 8 or above. Recent SEC coverage for RAJAF spans 6-K, 20-F.
Recent high-impact activity:
- TFA Therapeutics Opens $15M Offshore Private Placement at $2.52/Share
- Cordyceps Sunshine Secures Exclusive Global Commercialization Rights for Antcin A Drug Platform
- Going Concern Warning, Material Weakness in Controls, and Recurring Losses Highlight Financial Distress
Financial Snapshot
Dilution Risk
Low riskFiling-implied dilution signals for RAJAF, detected from its recent SEC filings · based on capital-structure filings through 2026-09-02.
Offshore Private Placement Launched · Pricing and Dilution
A filing-implied signal, not a realized share count. How Wiseek tracks dilution →
Insider Transactions
RAJAF files as a Foreign Private Issuer (FPI). Under SEC Exchange Act Section 16(a), officers, directors, and 10% owners of FPIs are exempt from Form 4 insider-transaction reporting requirements. Comparable disclosures, when applicable, appear in the company's Form 20-F (annual) or Form 6-K (interim) filings on SEC EDGAR.